DCT

1:26-cv-00976

Eli Lilly & Co v. Biocon Pharma Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00976, D. Del., 08/06/2026
  • Venue Allegations: Venue is alleged to be proper as Defendants Biocon Pharma Limited and Biocon Limited are foreign corporations that may be sued in any judicial district, and Defendant Biocon Pharma, Inc. is a Delaware corporation, residing in the district for purposes of venue.
  • Core Dispute: Plaintiff alleges that Defendants' submission of Abbreviated New Drug Applications (ANDAs) to the FDA for generic versions of Mounjaro® and Zepbound® constitutes an act of infringement of nine U.S. patents covering the active ingredient tirzepatide, its pharmaceutical compositions, and methods of use.
  • Technical Context: The technology relates to pharmaceutical formulations and therapeutic uses of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist used for treating type 2 diabetes and obesity.
  • Key Procedural History: This action was filed under the Hatch-Waxman Act following Plaintiff's receipt of notice letters from Defendants, which included Paragraph IV certifications asserting that the patents-in-suit are invalid, unenforceable, or will not be infringed by the proposed generic products. All asserted patents are listed in the FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations" (the "Orange Book") for Mounjaro® and/or Zepbound®.

Case Timeline

Date Event
2018-06-22 Patent Priority Date (Compositions Patents, e.g., '820)
2018-07-23 Patent Priority Date (Method of Use Patents, e.g., '987)
2022-05-13 FDA grants approval to market Mounjaro® (tirzepatide)
2022-06-14 U.S. Patent No. 11,357,820 issues
2023-11-08 FDA grants approval to market Zepbound® (tirzepatide)
2024-03-05 U.S. Patent No. 11,918,623 issues
2025-05-13 U.S. Patent No. 12,295,987 issues
2025-07-01 U.S. Patent No. 12,343,382 issues
2025-10-28 U.S. Patent Nos. 12,453,755, 12,453,756, and 12,453,758 issue
2026-05-05 U.S. Patent No. 12,616,740 issues
2026-05-19 U.S. Patent No. 12,629,404 issues
2026-07-08 Defendants send Notice Letters regarding ANDA submissions
2026-07-09 Plaintiff receives Defendants' Notice Letters
2026-08-06 Complaint for patent infringement is filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,357,820 - "`GIP/GLP1 Agonist Compositions`"

  • Patent Identification: U.S. Patent No. 11,357,820, issued June 14, 2022.
  • The Invention Explained:
    • Problem Addressed: The patent's background section describes the need for a pharmaceutical composition of the GIP/GLP1 co-agonist peptide tirzepatide that provides acceptable stability while also ensuring an "acceptable patient injection site experience" '820 Patent, col. 1:19-25 The patent notes that certain formulation components, such as NaCl and citrate, have been associated with painful stinging at the injection site, presenting a challenge for subcutaneously administered drugs '820 Patent, col. 3:10-21
    • The Patented Solution: The patent discloses a pharmaceutical composition for subcutaneous injection that comprises three key ingredients: the active peptide tirzepatide, sodium chloride (NaCl) as a tonicity-modifying agent, and dibasic sodium phosphate as a buffering agent '820 Patent, col. 1:26-31 This specific combination is described as providing both "commercially acceptable shelf-life stability" and an "acceptable patient injection site experience" '820 Patent, col. 1:5-8
    • Technical Importance: Developing a stable and patient-tolerated injectable formulation is critical for the commercial viability of chronically administered drugs like tirzepatide, as poor stability can limit shelf life and injection site pain can reduce patient compliance.
  • Key Claims at a Glance:
    • The complaint asserts at least independent claim 1 Compl. ¶56
    • Essential elements of Independent Claim 1:
      • A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof;
      • NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; and
      • dibasic sodium phosphate.
    • The complaint reserves the right to assert other claims Compl. ¶57 Compl. ¶58

U.S. Patent No. 11,918,623 - "`GIP/GLP1 Agonist Compositions`"

  • Patent Identification: U.S. Patent No. 11,918,623, issued March 5, 2024.
  • The Invention Explained:
    • Problem Addressed: Similar to the '820 Patent, this patent addresses the need for a stable and patient-friendly formulation of tirzepatide for treating conditions like diabetes and obesity '623 Patent, col. 1:31-41
    • The Patented Solution: The patent claims a method of treating obesity by administering a pharmaceutical composition containing tirzepatide within specific concentration ranges for its components, including tirzepatide, dibasic sodium phosphate, NaCl, and optionally the preservative phenol '623 Patent, cl. 1 The invention protects the therapeutic application of these specific formulations for obesity.
    • Technical Importance: This patent provides method-of-use protection for a specific formulation of tirzepatide in the commercially significant obesity market, distinct from simply claiming the composition itself.
  • Key Claims at a Glance:
    • The complaint asserts at least independent claim 1 Compl. ¶73
    • Essential elements of Independent Claim 1:
      • A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide, or pharmaceutically acceptable salt thereof;
      • wherein the tirzepatide concentration is from about 5 mg/mL to about 30 mg/mL;
      • dibasic sodium phosphate is from about 0.67 to about 2.68 mg/mL;
      • NaCl at a concentration from about 6.2 mg/mL to about 9.5 mg/mL; and
      • optionally comprising from about 3.0 mg/mL to about 7.0 mg/mL phenol.
    • The complaint reserves the right to assert other claims Compl. ¶74 Compl. ¶75

Multi-Patent Capsules

  • U.S. Patent No. 12,295,987 ("Methods of Using a GIP/GLP1 Co-agonist for Diabetes"), issued May 13, 2025:

    • Technology Synopsis: This patent claims a method of treating type 2 diabetes by administering a GIP:GLP-1 peptide using a specific four-dose titration schedule, where each dose is a defined percentage of the final dose Compl. ¶91 The method is further defined by the peptide's specific receptor agonist potency ratio Compl. ¶91
    • Asserted Claims: At least independent claim 1 Compl. ¶91
    • Accused Features: The proposed labeling for Defendants' generic Mounjaro® product (ANDA No. 219842) is alleged to instruct and encourage this specific dosing method for treating type 2 diabetes Compl. ¶92

  • U.S. Patent No. 12,343,382 ("Methods of Using a GIP/GLP1 Co-agonist for Therapy"), issued July 1, 2025:

    • Technology Synopsis: This patent claims a method for treating type 2 diabetes (claim 1) or improving weight management (claim 11) using a weekly dose-escalation regimen followed by a maintenance dose Compl. ¶109 Compl. ¶111 The claims specify the exact milligram amounts for the escalation and maintenance doses of tirzepatide Compl. ¶109 Compl. ¶111
    • Asserted Claims: At least independent claims 1 and 11 Compl. ¶109 Compl. ¶111
    • Accused Features: The proposed labeling for generic Mounjaro® (ANDA No. 219842) is alleged to infringe claim 1, and the labeling for generic Zepbound® (ANDA No. 221378) is alleged to infringe claim 11 Compl. ¶110 Compl. ¶112

  • U.S. Patent No. 12,453,755 ("GIP/GLP1 Agonist Compositions"), issued October 28, 2025:

    • Technology Synopsis: This patent claims a method of treating diabetes by administering a pharmaceutical composition with specific concentration ranges for tirzepatide, dibasic sodium phosphate, NaCl, and optional phenol Compl. ¶131 It is similar to the '623 Patent but directed to diabetes instead of obesity.
    • Asserted Claims: At least independent claim 1 Compl. ¶131
    • Accused Features: The proposed labeling for Defendants' generic Mounjaro® product (ANDA No. 219842) is alleged to instruct and encourage this method of treatment Compl. ¶132

  • U.S. Patent No. 12,453,756 ("GIP/GLP1 Agonist Compositions"), issued October 28, 2025:

    • Technology Synopsis: This patent claims a pharmaceutical composition comprising tirzepatide and a specific concentration range of NaCl, where the composition has a pH of about 6.5 to 7.5 Compl. ¶149
    • Asserted Claims: At least independent claim 1 Compl. ¶149
    • Accused Features: Defendants' Proposed ANDA Products are alleged to be compositions that meet these claim limitations Compl. ¶150

  • U.S. Patent No. 12,453,758 ("Methods of Using a GIP/GLP1 Co-agonist for Diabetes"), issued October 28, 2025:

    • Technology Synopsis: This patent claims a method for improving weight management using a specific four-dose titration schedule defined by percentages of a final dose and the peptide's specific receptor agonist potency ratio Compl. ¶166 This is similar to the '987 patent but directed to weight management.
    • Asserted Claims: At least independent claim 1 Compl. ¶166
    • Accused Features: The proposed labeling for Defendants' generic Zepbound® product (ANDA No. 221378) is alleged to instruct and encourage this specific dosing method Compl. ¶167

  • U.S. Patent No. 12,616,740 ("Methods of Using a GIP/GLP1 Co-agonist for Therapy"), issued May 5, 2026:

    • Technology Synopsis: This patent claims a method for treating type 2 diabetes (claim 1) or obesity (claim 6) by administering tirzepatide in a specific once-weekly dose escalation regimen involving a 2.5 mg starting dose for four weeks, followed by incremental increases to a maintenance dose Compl. ¶184 Compl. ¶186
    • Asserted Claims: At least independent claims 1 and 6 Compl. ¶184 Compl. ¶186
    • Accused Features: The proposed labeling for generic Mounjaro® (ANDA No. 219842) is alleged to infringe claim 1, and the labeling for generic Zepbound® (ANDA No. 221378) is alleged to infringe claim 6 Compl. ¶185 Compl. ¶187

  • U.S. Patent No. 12,629,404 ("GIP/GLP1 Agonist Compositions"), issued May 19, 2026:

    • Technology Synopsis: This patent claims a pharmaceutical composition comprising tirzepatide and NaCl within a specific concentration range, having a pH of about 6.5 to 7.5, and being "free of preservative" Compl. ¶206
    • Asserted Claims: At least independent claim 1 Compl. ¶206
    • Accused Features: Defendants' Proposed ANDA Products are alleged to be compositions that meet these claim limitations Compl. ¶207

III. The Accused Instrumentality

  • Product Identification: The accused instrumentalities are Defendants' "Proposed ANDA Products" seeking FDA approval as generic versions of Mounjaro® (tirzepatide) and Zepbound® (tirzepatide) autoinjectors Compl. ¶1 Specifically, these are ANDA No. 219842 for a generic Mounjaro® and ANDA No. 221378 for a generic Zepbound® Compl. ¶1
  • Functionality and Market Context:
    • The Proposed ANDA Products are sterile solutions of tirzepatide intended for subcutaneous injection via autoinjectors at various strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL) (Compl. ¶1; Compl. ¶10). The active pharmaceutical ingredient, tirzepatide, is a GIP and GLP-1 receptor agonist (Compl. ¶23).
    • The complaint alleges that these products, if approved, will be marketed in direct competition with Lilly's Mounjaro® and Zepbound® products for improving glycemic control in type 2 diabetes and for chronic weight management Compl. ¶p. 2 The complaint asserts that Defendants' ANDAs rely on Lilly's approved New Drug Applications (NDAs) and contain data to demonstrate bioequivalence Compl. ¶51

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

11,357,820 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof; Defendants' Proposed ANDA Products are alleged to be pharmaceutical compositions that comprise tirzepatide or a pharmaceutically acceptable salt thereof. ¶57 col. 3:21-29
NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; The Proposed ANDA Products are alleged to contain NaCl at a concentration within the claimed range. ¶57 col. 1:32-33
and dibasic sodium phosphate. The Proposed ANDA Products are alleged to contain dibasic sodium phosphate. ¶57 col. 1:35-37
  • Identified Points of Contention:
    • Scope Questions: A potential point of contention may be the scope of the term "dibasic sodium phosphate." The infringement analysis may turn on whether this term is construed to cover any specific form or hydrate of dibasic sodium phosphate that Defendants might use in their formulation, particularly if it differs from the heptahydrate form mentioned in the patent's examples '820 Patent, col. 8, Table 7
    • Technical Questions: A factual question for the court will be whether Defendants' Proposed ANDA Products actually contain NaCl and dibasic sodium phosphate within the parameters required by the claims. The complaint's allegations are made "on information and belief" pending discovery.

11,918,623 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide, or pharmaceutically acceptable salt thereof, The complaint alleges that the proposed labeling for Defendants' Proposed ANDA No. 221378 Product instructs and encourages treating obesity by administering an effective dose of a pharmaceutical composition comprising tirzepatide. ¶74 col. 2:56-60
wherein the tirzepatide concentration is from about 5 mg/mL to about 30 mg/mL; The composition in the Proposed ANDA No. 221378 Product is alleged to have a tirzepatide concentration within the claimed range. ¶74 col. 2:21-23
dibasic sodium phosphate is from about 0.67 to about 2.68 mg/mL; The composition is alleged to have a dibasic sodium phosphate concentration within the claimed range. ¶74 col. 1:63-64
NaCl at a concentration from about 6.2 mg/mL to about 9.5 mg/mL; The composition is alleged to have a NaCl concentration within the claimed range. ¶74 col. 1:49-51
and optionally comprising from about 3.0 mg/mL to about 7.0 mg/mL phenol. The composition is alleged to optionally comprise phenol within the claimed range. ¶74 col. 2:40-43
  • Identified Points of Contention:
    • Scope Questions: The case may involve a dispute over the meaning of "treating obesity." Defendants may argue that their product's label, which will track Lilly's FDA-approved label for "chronic weight management," does not meet the legal or technical definition of "treating obesity" as contemplated by the patent.
    • Technical Questions: The central evidentiary question for infringement will be whether the content of Defendants' proposed product label for their generic Zepbound® product instructs or encourages administration in a manner that falls within the scope of the claimed method.

V. Key Claim Terms for Construction

'820 Patent

  • The Term: "dibasic sodium phosphate"
  • Context and Importance: This term is one of the three mandatory components of the claimed composition. Its construction is critical because if Defendants' formulation uses a different form of phosphate buffer (e.g., monobasic sodium phosphate adjusted with a base) or a different hydrate of dibasic sodium phosphate, the infringement analysis could depend entirely on whether that alternative falls within the scope of this term.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The claim language itself is not modified by a specific hydrate (e.g., "heptahydrate"), which may support a construction covering any form of dibasic sodium phosphate that provides the intended buffering function ('820 Patent, cl. 1). The specification also refers to "dibasic sodium phosphate" generally ('820 Patent, col. 1:30).
    • Evidence for a Narrower Interpretation: The patent's examples, which are used to demonstrate the properties of the invention, explicitly list "Sodium phosphate dibasic 7H2O" '820 Patent, col. 8, Table 7 A defendant may argue this specific embodiment limits the claim's scope to the heptahydrate form.

'623 Patent

  • The Term: "treating obesity"
  • Context and Importance: As this is a method of treatment claim, the definition of "treating obesity" is fundamental to the infringement question. Practitioners may focus on this term because the dispute could center on whether the indications and instructions on the accused product's proposed label-which will likely mirror the FDA-approved language for Zepbound® for "chronic weight management"-meet the patent's requirements for "treating obesity."
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent specification broadly describes tirzepatide as "useful in the treatment of obesity" '623 Patent, col. 1:33-34 and provides a "method of treating obesity" '623 Patent, col. 2:56-60, which may suggest the term should be given its plain and ordinary meaning in the field.
    • Evidence for a Narrower Interpretation: A party could argue that the term should be limited by the clinical outcomes demonstrated in the patent, potentially requiring a specific quantum of weight loss or improvement in obesity-related comorbidities to qualify as "treating." The specification also mentions "providing therapeutic weight loss" '623 Patent, col. 3:5-6, which might be argued to set a specific functional requirement for the method.

VI. Other Allegations

  • Indirect Infringement: For all asserted patents, the complaint alleges both induced and contributory infringement. Inducement is primarily based on allegations that Defendants' proposed product labeling will instruct and encourage healthcare providers and patients to make and use the infringing compositions and perform the infringing methods Compl. ¶66 Compl. ¶82 Compl. ¶100 Compl. ¶120 Contributory infringement is based on the allegation that the Proposed ANDA Products are especially made or adapted for infringing uses and are not suitable for substantial noninfringing use Compl. ¶67 Compl. ¶85 Compl. ¶103 Compl. ¶125
  • Willful Infringement: The complaint alleges willful infringement for all asserted patents. The basis for this allegation is Defendants' pre-suit knowledge of the patents, evidenced by the patents' listing in the FDA's Orange Book and Defendants' inclusion of the patents in their Paragraph IV Notice Letters to Lilly Compl. ¶65 Compl. ¶81 Compl. ¶99 Compl. ¶119

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue for the composition claims will be one of definitional scope: can the term "dibasic sodium phosphate" in the '820 patent, which is exemplified as a specific heptahydrate form, be construed to cover any alternative phosphate-based buffer system or hydrate form that may be used in the Defendants' proposed generic products?
  • A key question for the multiple method-of-use patents will be one of induced infringement: will the specific instructions for use in Defendants' proposed product labels, which are intended to carve-out patented uses where possible, nevertheless lead healthcare professionals and patients to inevitably perform the patented dosing regimens for treating diabetes and obesity, thus meeting the legal standard for inducement?
  • The litigation will also likely focus on validity challenges, where Defendants will argue that the asserted claims are invalid as obvious over the prior art. This will involve a technical analysis of whether a person of ordinary skill in the art would have been motivated to combine prior art references to arrive at the claimed formulations and methods with a reasonable expectation of success.
Loading Complaint